Search Clinical Trials
Sponsor Condition of Interest |
---|
Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia...
Novartis Pharmaceuticals
Primary Immune Thrombocytopenia (ITP)
The purpose of this study is to evaluate the effect of two different doses of ianalumab
versus placebo in addition to first-line corticosteroids in maintaining platelet count
≥30 G/L in adult participants with primary ITP. expand
The purpose of this study is to evaluate the effect of two different doses of ianalumab versus placebo in addition to first-line corticosteroids in maintaining platelet count ≥30 G/L in adult participants with primary ITP. Type: Interventional Start Date: Mar 2023 |
ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)
Chimerix
H3 K27M
Glioma
This is a randomized, double-blind, placebo-controlled, parallel-group, international,
Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess
whether treatment with ONC201 following frontline radiotherapy will extend overall
survival and progression-free survival in... expand
This is a randomized, double-blind, placebo-controlled, parallel-group, international, Phase 3 study in patients with newly diagnosed H3 K27M-mutant diffuse glioma to assess whether treatment with ONC201 following frontline radiotherapy will extend overall survival and progression-free survival in this population. Eligible participants will have histologically diagnosed H3 K27M-mutant diffuse glioma and have completed standard frontline radiotherapy. Type: Interventional Start Date: Jan 2023 |
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally...
Hoffmann-La Roche
Non-Small Cell Lung Cancer
This study will evaluate the efficacy and safety of multiple therapies in participants
with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as
determined by Version 8 of the American Joint Committee on Cancer/Union for International
Cancer Control NSCLC staging system. expand
This study will evaluate the efficacy and safety of multiple therapies in participants with locally advanced, unresectable, Stage III NSCLC with eligible biomarker status as determined by Version 8 of the American Joint Committee on Cancer/Union for International Cancer Control NSCLC staging system. Type: Interventional Start Date: Nov 2022 |
Chronic Pain Management In Primary Care Using Behavioral Health Consultants
The University of Texas Health Science Center at San Antonio
Chronic Pain
The purpose of this randomized pragmatic trial is to assess the effect of monthly booster
contacts on long-term Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP) pain
outcomes compared to BCBT-CP without a booster in 716 Military Health Systems (MHS)
beneficiaries referred to a Behavioral... expand
The purpose of this randomized pragmatic trial is to assess the effect of monthly booster contacts on long-term Brief Cognitive Behavioral Therapy for Chronic Pain (BCBT-CP) pain outcomes compared to BCBT-CP without a booster in 716 Military Health Systems (MHS) beneficiaries referred to a Behavioral Health Consultant (BHC) for pain management using BCBT-CP. Patients will be randomly assigned to receive either standard BCBT-CP (working with a BHC in the medical home clinic) or standard BCBT-CP with adjunctive monthly booster contacts. Additionally, patient participants and clinic providers and staff will be offered the opportunity to participate in separate post-treatment Focus Groups using a semi-structured interview format designed to assess the usability, ease of use, perceived effectiveness, helpfulness, and barriers to the pain management intervention. Patient participants will be assessed 3-, 6-, 12- and 18-Months following their first appointment for BCBT-CP. Type: Interventional Start Date: Aug 2021 |
Comparison of Chemotherapy Before and After Surgery Versus After Surgery Alone for the Treatment of Gallbladder...
ECOG-ACRIN Cancer Research Group
Stage II Gallbladder Cancer AJCC v8
Stage IIA Gallbladder Cancer AJCC v8
Stage IIB Gallbladder Cancer AJCC v8
Stage III Gallbladder Cancer AJCC v8
Stage IIIA Gallbladder Cancer AJCC v8
This phase II/III trial compares the effect of adding chemotherapy before and after
surgery versus after surgery alone (usual treatment) in treating patients with stage
II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in
different ways to stop the growth of tumor... expand
This phase II/III trial compares the effect of adding chemotherapy before and after surgery versus after surgery alone (usual treatment) in treating patients with stage II-III gallbladder cancer. Chemotherapy drugs, such as gemcitabine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy before surgery may make the tumor smaller; therefore, may reduce the extent of surgery. Additionally, it may make it easier for the surgeon to distinguish between normal and cancerous tissue. Giving chemotherapy after surgery may kill any remaining tumor cells. This study will determine whether giving chemotherapy before surgery increases the length of time before the cancer may return and whether it will increase a patient's life span compared to the usual approach. Type: Interventional Start Date: Feb 2021 |
Personalized Behavioral Nutrition Intervention in Older AAs With T2D
The University of Texas Health Science Center at San Antonio
Type 2 Diabetes
The rapid growth rate and unique challenges as a new immigrant group call for a better
understanding of the social and health needs of the older Asian Americans (AAs)
population. Overwhelming numbers of AAs, a fast-growing first-generation immigrant group,
suffer from type 2 diabetes (T2D) and its... expand
The rapid growth rate and unique challenges as a new immigrant group call for a better understanding of the social and health needs of the older Asian Americans (AAs) population. Overwhelming numbers of AAs, a fast-growing first-generation immigrant group, suffer from type 2 diabetes (T2D) and its consequences of poorly controlled blood glucose. For the older AAs, there are higher prevalence rates, worse diabetes control, and higher rates of complications due to limited English proficiency and health literacy. Despite the evidence concerning the effects of dietary interventions on glycemic control by well-controlled feeding studies in mainstream Americans, a lack of clinical trials of culturally tailored interventions often imposes serious barriers to translate and implement such fruitful and innovative approaches in individuals from ethnic minority communities such as AAs. The proposed study will use a randomized, controlled design with a sample of 60 AAs aged 65 years or older. Metabolomics methodologies will be incorporated into this research to provide a global picture of metabolites' responses to personalized behavioral nutrition (PBN) intervention. The study results will obtain the necessary information to conduct a meaningful community-based clinical trial to test the effectiveness of PBN in improving dietary patterns and glycemic control in older AAs. Type: Interventional Start Date: Aug 2020 |
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
The University of Texas Health Science Center at San Antonio
Post Bariatricsurgery
Hypoglycemia
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM)
immediately after surgery before any significant weight loss. In addition, a growing
number of patients have been recognized with life-threatening hyperinsulinemic
hypoglycemia several years following their surgery.... expand
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones, primarily glucagon-like peptide 1 (GLP-1), as well as alteration in neural activity may contribute to enhanced insulin secretion in general, and to a greater extent in patients with hypoglycemia. The proposed research is designed to address the role of RYGB on insulin secretion by evaluating the contribution of stimulatory factors (neural and GI hormone) on islet cell function and the islet cell responsiveness to the physiologic stimulatory factors, in RYGB patients with and without hypoglycemia and non-operated controls. Type: Interventional Start Date: Oct 2009 |
A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants With Advanced Unresectable...
NextCure, Inc.
Advanced or Metastatic Solid Tumors
Microsatellite Instability Low
Microsatellite Instability High
Microsatellite Stable
Ovarian Cancer
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and
tolerability of NC410 when combined with a standard dose of pembrolizumab. This study
will also assess the clinical benefit of combination therapy in participants with
advanced unresectable and/or metastatic ICI refractory... expand
This is an open-label, non-randomized, Phase 1b/2 study to determine the safety and tolerability of NC410 when combined with a standard dose of pembrolizumab. This study will also assess the clinical benefit of combination therapy in participants with advanced unresectable and/or metastatic ICI refractory solid tumors OR ICI naïve MSS/MSI-low solid tumors Type: Interventional Start Date: Oct 2022 |
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With...
BeiGene
Advanced Solid Tumor
The primary objective of this study is to assess the safety and tolerability of BGB-15025
alone and in combination with tislelizumab; and to determine the maximum tolerated dose
(MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of
BGB-15025 alone and in combination with... expand
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors. Type: Interventional Start Date: Mar 2021 |
Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile-ROADS (Radiation One and Done Study)
GT Medical Technologies, Inc.
Brain Metastases
This trial will be a randomized controlled study comparing the efficacy and safety of
intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following
metastatic tumor resection which is the current standard of care. expand
This trial will be a randomized controlled study comparing the efficacy and safety of intraoperative radiation therapy using GammaTilesTM (GT) versus SRT 3-4 weeks following metastatic tumor resection which is the current standard of care. Type: Interventional Start Date: Apr 2021 |
Placement of Antibiotic Powder in Wounds During the Emergency Room
The University of Texas Health Science Center at San Antonio
Open Fracture
This is the first prospective controlled study to determine whether the topical
application of vancomycin powder reduces infection-related complications when applied to
open fracture injuries in the acute emergency department setting. expand
This is the first prospective controlled study to determine whether the topical application of vancomycin powder reduces infection-related complications when applied to open fracture injuries in the acute emergency department setting. Type: Interventional Start Date: Oct 2020 |
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast...
M.D. Anderson Cancer Center
Invasive Breast Carcinoma
Stage I Breast Cancer AJCC v7
Stage IA Breast Cancer AJCC v7
Stage IB Breast Cancer AJCC v7
Stage II Breast Cancer AJCC v6 and v7
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5
weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes
near the breast. The side effects that can develop during or after radiation treatment,
including how often arm swelling... expand
To compare how often cancer recurs (comes back) after 3 weeks of radiation compared to 5 weeks of radiation in patients who receive radiation therapy delivered to the lymph nodes near the breast. The side effects that can develop during or after radiation treatment, including how often arm swelling (edema) happens, will also be studied. Type: Interventional Start Date: Feb 2017 |
Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer...
ECOG-ACRIN Cancer Research Group
Hodgkin Lymphoma
Non-Hodgkin Lymphoma
This study examines the impact of social and genetic factors on outcomes in adolescent
and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to
both older adult and childhood cancer patients, AYAs with cancer experience different
diagnoses and specific biological, clinical,... expand
This study examines the impact of social and genetic factors on outcomes in adolescent and young adult (AYA) cancer survivors of Hodgkin or non-Hodgkin lymphoma. Compared to both older adult and childhood cancer patients, AYAs with cancer experience different diagnoses and specific biological, clinical, psychological and social factors that affect their risks for post-treatment morbidity and premature death. Collecting samples of blood samples and health and treatment information from cancer survivors of Hodgkin or non-Hodgkin lymphoma may help doctors identify conditions that increase the likelihood of AYAs getting sick and dying after treatment of cancer and better understand how to address the needs of adolescent and young adult cancer survivors. Type: Observational Start Date: Oct 2023 |
A Phase 1, Open-label Trial of Belzupacap Sarotalocan (AU-011) in Bladder Cancer
Aura Biosciences
Non-muscle-invasive Bladder Cancer
Muscle-Invasive Bladder Carcinoma
The main objectives of this study are to determine the feasibility and safety of AU-011
treatment of bladder cancer utilizing intratumoral injection with or without intramural
injection and with or without laser application. expand
The main objectives of this study are to determine the feasibility and safety of AU-011 treatment of bladder cancer utilizing intratumoral injection with or without intramural injection and with or without laser application. Type: Interventional Start Date: Sep 2022 |
An Open-Label Study of INV-1120 as a Single Agent and in Combination With Pembrolizumab in Adult Patients...
Shenzhen Ionova Life Sciences Co., Ltd.
Cancer
Solid Tumor, Adult
Cancer Metastatic
Solid Carcinoma
Solid Tumor, Unspecified, Adult
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and
to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab.
The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with
pembrolizumab will be assessed... expand
Phase 1, open-label dose-escalation study to determine the MTD of INV-1120 and RP2D, and to assess the DLT of INV-1120 as a single agent or in the combination with pembrolizumab. The safety, tolerability, and PK of INV-1120 as a single agent or in the combination with pembrolizumab will be assessed in adult patients with advanced solid tumors. Type: Interventional Start Date: Jun 2020 |
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients...
Children's Oncology Group
Childhood Extracranial Germ Cell Tumor
Extragonadal Embryonal Carcinoma
Germ Cell Tumor
Malignant Germ Cell Tumor
Malignant Ovarian Teratoma
This phase III trial studies how well active surveillance help doctors to monitor
subjects with low risk germ cell tumors for recurrence after their tumor is removed. When
the germ cell tumor has spread outside of the organ in which it developed, it is
considered metastatic. Drugs used in chemotherapy,... expand
This phase III trial studies how well active surveillance help doctors to monitor subjects with low risk germ cell tumors for recurrence after their tumor is removed. When the germ cell tumor has spread outside of the organ in which it developed, it is considered metastatic. Drugs used in chemotherapy, such as bleomycin, carboplatin, etoposide, and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The trial studies whether carboplatin or cisplatin is the preferred chemotherapy to use in treating metastatic standard risk germ cell tumors. Type: Interventional Start Date: May 2017 |
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
Glioma
This is a multi-center, sequential cohort, open-label, volume and dose escalation study
of the safety, tolerability, and distribution of 186RNL given by convection enhanced
delivery to patients with recurrent or progressive malignant glioma after standard
surgical, radiation, and/or chemotherapy treatment.... expand
This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL. Type: Interventional Start Date: Jun 2015 |
Study of LP-184 in Patients With Advanced Solid Tumors
Lantern Pharma Inc.
Advanced Solid Tumor
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D
of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory
to standard therapy or for whom no standard therapy is available. The secondary
objectives are to characterize the PK... expand
The primary objective of this study is to evaluate the safety, tolerability, MTD and RP2D of LP-184 in patients with advanced solid tumors who have relapsed from or are refractory to standard therapy or for whom no standard therapy is available. The secondary objectives are to characterize the PK of LP-184 and its metabolites in plasma and assess clinical activity of LP-184. Type: Interventional Start Date: Jun 2023 |
Feasibility and Clinical Utility of Cell-free DNA (cfDNA) in Identifying Actionable Alterations and Minimal...
M.D. Anderson Cancer Center
Lymphoma
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients
before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is
easily collected from blood samples drawn using the vein puncture method. expand
To test the feasibility of collecting cell-free DNA (cfDNA) samples from DLBCL patients before and after treatment. cfDNA is DNA traveling in your blood outside of a cell and is easily collected from blood samples drawn using the vein puncture method. Type: Interventional Start Date: Feb 2023 |
Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With...
Daiichi Sankyo
Metastatic Non Small Cell Lung Cancer
This study is designed to assess the efficacy and safety of datopotamab deruxtecan
(Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants
with advanced or metastatic non-small cell lung cancer (NSCLC). expand
This study is designed to assess the efficacy and safety of datopotamab deruxtecan (Dato-DXd) in combination with pembrolizumab versus pembrolizumab alone in participants with advanced or metastatic non-small cell lung cancer (NSCLC). Type: Interventional Start Date: Mar 2022 |
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic...
National Cancer Institute (NCI)
Anaplastic Astrocytoma
Anaplastic Astrocytoma, Not Otherwise Specified
Diffuse Intrinsic Pontine Glioma
Diffuse Midline Glioma, H3 K27M-Mutant
Glioblastoma
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in
combination with standard radiation therapy in treating children and young adults with
newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a
genetic change called H3 K27M mutation.... expand
This phase I/II trial tests the safety, side effects, and best dose of selinexor given in combination with standard radiation therapy in treating children and young adults with newly diagnosed diffuse intrinsic pontine glioma (DIPG) or high-grade glioma (HGG) with a genetic change called H3 K27M mutation. It also tests whether combination of selinexor and standard radiation therapy works to shrink tumors in this patient population. Glioma is a type of cancer that occurs in the brain or spine. Glioma is considered high risk (or high-grade) when it is growing and spreading quickly. The term, risk, refers to the chance of the cancer coming back after treatment. DIPG is a subtype of HGG that grows in the pons (a part of the brainstem that controls functions like breathing, swallowing, speaking, and eye movements). This trial has two parts. The only difference in treatment between the two parts is that some subjects treated in Part 1 may receive a different dose of selinexor than the subjects treated in Part 2. In Part 1 (also called the Dose-Finding Phase), investigators want to determine the dose of selinexor that can be given without causing side effects that are too severe. This dose is called the maximum tolerated dose (MTD). In Part 2 (also called the Efficacy Phase), investigators want to find out how effective the MTD of selinexor is against HGG or DIPG. Selinexor blocks a protein called CRM1, which may help keep cancer cells from growing and may kill them. It is a type of small molecule inhibitor called selective inhibitors of nuclear export (SINE). Radiation therapy uses high energy to kill tumor cells and shrink tumors. The combination of selinexor and radiation therapy may be effective in treating patients with newly-diagnosed DIPG and H3 K27M-Mutant HGG. Type: Interventional Start Date: May 2022 |
Dapagliflozin Plus Pioglitazone in T1DM
The University of Texas Health Science Center at San Antonio
Type 1 Diabetes Mellitus
Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus
pioglitazone to insulin on glucose control and plasma ketone concentration in patients
with type 1 diabetes (T1DM) Research Design: 120 patients with type 1 diabetes who
otherwise are healthy constitute the study... expand
Purpose: To examine the effect of addition of combination therapy with dapagliflozin plus pioglitazone to insulin on glucose control and plasma ketone concentration in patients with type 1 diabetes (T1DM) Research Design: 120 patients with type 1 diabetes who otherwise are healthy constitute the study population. After screening, eligible subjects will start 4 week run in. At week 4, subjects will receive dapagliflozin for 12 weeks. At week 16, subjects will be randomized to receive in a double blind fashion pioglitazone or placebo for 16 weeks. Methods: the following techniques will be employed in the present study: (1) mixed meal tolerance test; (2) indirect calorimetry; (3) continuous glucose monitoring. Clinical Relevance: the results of the present study will demonstrate that the addition of pioglitazone to SGLT2 inhibitor in T1DM patients produces greater reduction in the HbA1c without increasing risk of ketoacidosis and hypoglycemia. Type: Interventional Start Date: Aug 2019 |
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin...
National Cancer Institute (NCI)
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and
nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard
treatment alone in improving survival in patients with stage I and II classical Hodgkin
lymphoma. Brentuximab vedotin... expand
This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stage I and II classical Hodgkin lymphoma. Brentuximab vedotin is in a class of medications called antibody-drug conjugates. It is made of a monoclonal antibody called brentuximab that is linked to a cytotoxic agent called vedotin. Brentuximab attaches to CD30 positive lymphoma cells in a targeted way and delivers vedotin to kill them. A monoclonal antibody is a type of protein that can bind to certain targets in the body, such as molecules that cause the body to make an immune response (antigens). Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs such as doxorubicin hydrochloride, bleomycin sulfate, vinblastine sulfate, dacarbazine, and procarbazine hydrochloride work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Vincristine is in a class of medications called vinca alkaloids. It works by stopping cancer cells from growing and dividing and may kill them. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Adding immunotherapy to the standard treatment of chemotherapy with or without radiation may increase survival and/or fewer short-term or long-term side effects in patients with classical Hodgkin lymphoma compared to the standard treatment alone. Type: Interventional Start Date: May 2023 |
Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma
Children's Oncology Group
Metastatic Malignant Neoplasm in the Lung
Metastatic Osteosarcoma
Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to
thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients
with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic
surgery is a type of surgery done through... expand
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better. Type: Interventional Start Date: Apr 2022 |
Affixus Natural Nail System Humeral Nail PMCF
Zimmer Biomet
Humeral Fractures, Proximal
Humeral Fractures
A commercially available product clinical study which aims to confirm the safety,
performance and clinical benefits to the patient of the Affixus Natural Nail upper arm
(humerus) bone nail system for both the implant itself and the instrumentation used
during surgery. expand
A commercially available product clinical study which aims to confirm the safety, performance and clinical benefits to the patient of the Affixus Natural Nail upper arm (humerus) bone nail system for both the implant itself and the instrumentation used during surgery. Type: Interventional Start Date: Aug 2022 |
- Previous
- Next